Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
172.91
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 3, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
172.91
Bid (Size)
166.82 (1)
Ask (Size)
181.86 (2)
Prev. Close
172.91
Today's Range
172.91 - 172.91
52wk Range
169.22 - 242.97
Shares Outstanding
118,847,693
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Analyst Expectations for Alnylam Pharmaceuticals's Future
September 29, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Performance
YTD
-25.98%
-25.98%
1 Month
-13.69%
-13.69%
3 Month
-10.21%
-10.21%
6 Month
-14.70%
-14.70%
1 Year
-12.13%
-12.13%
More News
Read More
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Via
Benzinga
What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
September 12, 2023
Via
Benzinga
The Latest Analyst Ratings for Alnylam Pharmaceuticals
August 16, 2023
Via
Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
July 25, 2023
Via
Benzinga
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Via
MarketBeat
Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects
September 14, 2023
Via
Benzinga
Exposures
Product Safety
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer
September 14, 2023
Via
Investor's Business Daily
Exposures
Product Safety
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
September 14, 2023
Via
Benzinga
Exposures
Product Safety
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going
September 14, 2023
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
September 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
September 13, 2023
Via
InvestorPlace
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
September 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
September 11, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public'
September 08, 2023
Via
Benzinga
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
Via
Benzinga
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
September 07, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
Via
MarketBeat
Exposures
COVID-19
Product Safety
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
September 05, 2023
Via
Benzinga
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna
August 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
August 03, 2023
From
Alnylam Pharmaceuticals
Via
Business Wire
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook
July 31, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.